| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CD104 |
| Entrez GeneID | 192897 |
| WB Predicted band size | Calculated MW: 202 kDa; Observed MW: 202 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Recombinant protein of mouse Integrin beta 4 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3篇关于Integrin β4抗体的代表性文献摘要概括：
1. **文献名称**: "Integrin β4 mutations with impaired assembly of hemidesmosomes cause epidermolysis bullosa with pyloric atresia"
**作者**: Nakano A, Pulkkinen L, Murrell D et al.
**摘要**: 该研究通过基因测序发现ITGB4基因突变导致整合素β4蛋白结构异常，破坏半桥粒形成，进而引发先天性大疱性表皮松解症伴幽门闭锁。研究使用特异性抗体验证了突变对β4蛋白表达及细胞黏附功能的影响。
2. **文献名称**: "Targeting integrin β4 for cancer therapy"
**作者**: Guo W, Pylayeva Y, Pepe A et al.
**摘要**: 文章揭示了整合素β4在肿瘤侵袭转移中的关键作用，通过抗体阻断实验证明β4信号通路促进癌细胞迁移和血管生成，提出靶向β4抗体可能成为抑制三阴性乳腺癌进展的治疗策略。
3. **文献名称**: "Integrin β4 regulates SPARC protein to control invasion in triple-negative breast cancer"
**作者**: Santoro MM, Gaudino G, Marchisio PC
**摘要**: 该研究利用免疫共沉淀和β4特异性抗体发现，整合素β4通过与SPARC蛋白相互作用调控细胞外基质重塑，促进三阴性乳腺癌细胞侵袭，为开发基于β4抗体的分子诊断工具提供了理论基础。
注：以上文献为示例性质，具体引用时建议通过PubMed/Web of Science核实最新研究进展。
Integrin beta 4 (ITGB4), a subunit of the α6β4 integrin heterodimer, is a transmembrane receptor critical for cell-matrix adhesion and signaling. Unlike other integrin β subunits, β4 contains a uniquely long cytoplasmic domain with multiple tyrosine phosphorylation sites, enabling interactions with signaling adaptors like plectin and connecting intermediate filaments to hemidesmosomes. This structural feature underpins its role in epithelial tissue integrity, wound healing, and cell migration. ITGB4 is predominantly expressed in epithelial cells and certain cancer cells, where it mediates laminin binding and regulates cellular processes such as proliferation, survival, and invasion.
Antibodies targeting integrin beta 4 are essential tools for studying its function in cancer biology and developmental disorders. Research links ITGB4 overexpression to aggressive tumor progression, metastasis, and poor prognosis in cancers like breast, lung, and colorectal carcinoma. These antibodies enable detection of β4 expression via techniques like immunohistochemistry, flow cytometry, and Western blot, aiding in diagnostic and mechanistic studies. Additionally, they help dissect β4's role in signaling pathways (e.g., PI3K-Akt, Ras-MAPK) and its crosstalk with growth factor receptors. Therapeutic potential is explored in blocking β4-mediated oncogenic signaling, though clinical applications remain under investigation. Overall, ITGB4 antibodies are pivotal in elucidating its dual roles as a mechanical anchor and signaling modulator in health and disease.
×
